ライフサイエンスコーパス: oncolytic adenovirus

1 ficantly enhanced the antitumor effect of an oncolytic adenovirus.

2 osylation states and cancer treatments using oncolytic adenovirus.

3 al strategy to optimize clinical efficacy of oncolytic adenoviruses.

4 ill be required for a complete evaluation of oncolytic adenoviruses.

5 ptibility of primary ovarian cancer cells to oncolytic adenoviruses.

6 and has implications for cancer therapy with oncolytic adenoviruses.

7 ility of tumor cells to systemically applied oncolytic adenoviruses.

8 llent candidates for generating HCC-specific oncolytic adenoviruses.

9 fety trait to be considered in the design of oncolytic adenoviruses.

10 ation of dendritic cells (DCs) combined with oncolytic adenovirus (Ad) expressing antitumor cytokines

11 We have constructed a novel oncolytic adenovirus (Ad) vector named VRX-009 that comb

12 Oncolytic adenovirus (Ad) vectors present a promising mo

13 We use a newly designed tumor-targeted oncolytic adenovirus (Ad-TD) to deliver non-secreting (n

14 In this study, we constructed a novel oncolytic adenovirus, Ad5/3-hTERT-E1A-hCD40L, which feat

15 ribution of a potent breast cancer-selective oncolytic adenovirus, AdEHE2F-Luc, to tumour regions tha

16 Although oncolytic adenoviruses (Ads) are an attractive option fo

17 implications for clinical use of E3B-deleted oncolytic adenovirus and other E3B-deleted adenovirus ve

18 stify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the trea

19 y suggest a possible interaction between the oncolytic adenovirus and/or double-suicide gene therapie

20 ave important implications for the design of oncolytic adenoviruses and may explain the rapid clearan

21 roducts, are applicable to the production of oncolytic adenoviruses and other cell-based products, an

22 mechanistic rationale for the combination of oncolytic adenoviruses and temozolomide, and should prop

23 Replication-selective oncolytic adenoviruses are being developed for the treat

24 Oncolytic adenoviruses are promising therapies for the t

25 The use of oncolytic adenoviruses as a cancer therapeutic is depend

26 ent a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments.

27 indicate that this improved stroma-targeted oncolytic adenovirus can override the resistance of mela

28 c administration of a replication-competent, oncolytic adenovirus containing a cytosine deaminase (CD

29 viously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can targe

30 A novel oncolytic adenovirus, CRAd-Survivin-pk7, showed signific

31 y DNA repair genes, we hypothesized that the oncolytic adenovirus Delta-24-RGD could be successfully

32 studies, we show that BM-hMSCs carrying the oncolytic adenovirus Delta-24-RGD prolonged the survival

33 To test the hypothesis, we first constructed oncolytic adenovirus Delta-24-RGDOX expressing the immun

34 hours following in vitro infection with the oncolytic adenovirus dl922-947.

35 /DeltaE3), a previously described E3-deleted oncolytic adenovirus encoding GM-CSF.

36 ovirus vectors and which can be killed by an oncolytic adenovirus expressing adenovirus E1A and tumor

37 Data are presented showing that oncolytic adenoviruses expressing the relaxin gene and c

38 er, the reintroduction of the E3 region into oncolytic adenoviruses has been found to positively infl

39 Oncolytic adenoviruses have been considered for use as a

40 Human oncolytic adenoviruses have been used in clinical trials

41 We previously developed an oncolytic adenovirus (HYPR-Ad) for the specific killing

42 The oncolytic adenovirus ICOVIR-15K was engineered to expres

43 n, which greatly enhances the activity of an oncolytic adenovirus in the presence of low-dose radioth

44 del that more accurately reflects the use of oncolytic adenoviruses in cancer patients.

45 d therapeutic index of replication-selective oncolytic adenoviruses in patients, we believe that enco

46 The CB1 oncolytic adenovirus induces a potent antiglioma effect

47 Furthermore, i.t. oncolytic adenovirus injection resulted in suppression o

48 Oncolytic adenovirus injection showed efficacy in three

49 Oncolytic adenovirus is an attractive platform for immun

50 allows the effective testing of mouse armed oncolytic adenovirus (MAV) vectors in immunocompetent sy

51 The therapeutic value of similar oncolytic adenoviruses may be improved by abrogating E4o

52 egulation of autophagy in cells treated with oncolytic adenoviruses may provide new avenues to improv

53 used ECM-degrading and Wnt signal-disrupting oncolytic adenovirus (oAd/DCN/LRP) to achieve a desirabl

54 models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad

55 at intratumor vaccination with a recombinant oncolytic adenovirus overexpressing the HSP70 protein ca

56 Oncolytic adenoviruses produce clinical benefits, partic

57 Replication-selective oncolytic adenoviruses represent a novel cancer treatmen

58 Replication-selective oncolytic adenoviruses represent a promising new platfor

59 Oncolytic adenoviruses represent a promising therapeutic

60 Oncolytic adenoviruses represent an innovative approach

61 Intratumoral administration of 01/PEME, an oncolytic adenovirus, required approximately 1000-fold l

62 Oncolytic adenoviruses, such as Delta-24-RGD (Delta24RGD

63 Oncolytic adenoviruses, such as Delta-24-RGD, are promis

64 xt generation of transcriptionally regulated oncolytic adenoviruses take advantage of the ability of

65 ents a barrier to infection by commonly used oncolytic adenoviruses targeted to coxsackie-adenovirus

66 oof-of-principle evidence that an attenuated oncolytic adenovirus that selectively lyses cells under

67 has been substituted for the E3-gp19 gene in oncolytic adenoviruses that otherwise retained the E3 re

68 more effectively activated and redirected by oncolytic adenoviruses that were armed with bispecific T

69 linical trials and the established safety of oncolytic adenoviruses, the in vivo function of these ag

70 Our study has implications for oncolytic adenovirus therapy.IMPORTANCE Previously, it h

71 r (hTERT), with the beneficial effects of an oncolytic adenovirus to deliver the gene for the prodrug

72 Here we use an oncolytic adenovirus to deliver the prodrug-activating e

73 Clinical trials have shown oncolytic adenoviruses to be tumor selective with minima

74 we showed for the first time the ability of oncolytic adenoviruses to enhance E2F transcriptional ac

75 nents within tumors, which helps recombinant oncolytic adenoviruses to spread effectively throughout

76 Targeting of oncolytic adenoviruses to tumors can potentially increas

77 The vast majority of oncolytic adenoviruses used in clinical trials to date h

78 Our results support the use of oncolytic adenoviruses using tumor-selective promoter(s)

79 omolog model for the testing of murine armed oncolytic adenovirus vectors in immunocompetent animals.

80 may become a valuable tool for the field of oncolytic adenovirus vectors in which vector safety and

81 sm of replication-competent viruses, such as oncolytic adenoviruses, vesicular stomatitis virus, and

82 The intra-arterial infusion of oncolytic adenoviruses warrants additional study.

83 intratumoral infection, tumor eradication by oncolytic adenovirus will probably require potent suppre

84 dl922-947, an oncolytic adenovirus with a 24-bp deletion in E1A CR2, r

85 ctivity-augmented, conditionally replicative oncolytic adenovirus with significant antiglioma effects

86 Overall, our results show how arming oncolytic adenoviruses with BiTE can overcome key limita